Enimmune Corp (安特羅生技) plans to apply to the Taiwan Food and Drug Administration for marketing approval for its enterovirus 71 (EV-71) vaccine next quarter after the treatment passed an interim analysis yesterday.
If approved, it would be the nation’s first vaccine for EV-71, which is a common pathogen that causes polio-like syndromes, and mostly infects infants and children aged five and younger.
Although the firm has developed three EV-71 vaccines in China, the latest treatment would have an advantage in the home market, as it is designed to act against genotype B4 of EV-71, which is more widespread in Taiwan and Vietnam, while Chinese vaccines target genotype C4, Enimmune general manager Vic Chang (張哲瑋) told the Taipei Times by telephone.
The interim analysis was conducted by the firm’s independent data monitoring committee comprised of external experts, Chang said.
The experts monitored vaccinated test subjects for at least six months to see if they developed any allergic reactions, but none of them had severe reactions to the vaccine, barring some mild side-effects, such as inflamed skin, he said.
The overall seroprotection rate for the subjects who were given a single dose in the phase-III clinical trial was about 90 percent, higher than the regulatory minimum, Chang added.
“That means that our vaccines had good efficacy,” Chang added.
Enimmune, a subsidiary of Adimmune Corp (國光生技), has over the past decade focused on researching and developing the EV-71 vaccine.
The firm said that it completed a phase-III randomized, double-blind and placebo-controlled trial in April last year with a 1,266 subjects.
Given that there is no medication for EV-71 infection in Taiwan except for supportive therapies, the vaccine would likely qualify to apply to the agency’s accelerated approval mechanism, in which review would be sped up for treatments that satisfy unmet medical needs and greatly advance treatment, Chang said.
“If everything goes smoothly, we anticipate gaining approval in the fourth quarter. Adimmune would help us manufacture the vaccines,” Chang said.
The government is also expected to consider including the vaccine in the National Health Insurance system, he added.
Meanwhile, Medigen Vaccine Biologics Corp (高端疫苗) said that it would conduct an interim analysis of its EV-71 vaccine later this year after enrolling 3,000 subjects for a phase-III trial in December last year, spokesman Leo Lee (李思賢) said.
“We concentrate on developing the world’s first EV-71 vaccine for protecting children two months to six months old, given all existing EV-71 vaccines would be administered to children older than six months,” Lee said.
Polytronics Technology Corp (聚鼎科技) yesterday announced that it is buying Henkel AG’s thermal clad dielectric material (TCLAD) business division for US$26 million as the Taiwanese firm aims to improve its technology, product portfolio and revenue performance. Polytronics, headquartered in the Hsinchu Science Park (新竹科學園區), is a supplier of protection components and heat dissipation materials. The firm entered the metallic heat-dissipation substrate market in 2007 and developed a unique solventless production process. Its board of directors approved signing an agreement with Henkel to acquire the German chemical firm’s TCLAD division in the US. The purchase includes all assets and business interests, including equipment,
‘SENSITIVE MARKETS’: The previously unannounced project would involve the company handing over control of data to a third party to sidestep privacy concerns Google has abandoned plans to offer a major new cloud service in China and other politically sensitive countries due in part to concerns over geopolitical tensions and the COVID-19 pandemic, two employees familiar with the matter said, revealing the challenges for US tech giants to secure business in those markets. In May, the search giant shut down the initiative, known as “Isolated Region” and which sought to address nations’ desires to control data within their borders, the employees said. The action was considered a “massive strategy shift,” said one of the employees, who added that Isolated Region had involved hundreds of employees
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday posted monthly revenue that suggested second-quarter sales surpassed analysts’ estimates, underscoring how its technological lead is helping the chipmaker weather the COVID-19 pandemic and US sanctions on its second-biggest customer Huawei Technologies Co (華為). Apple Inc’s main iPhone chipmaker posted sales of NT$120.88 billion (US$4.08 billion) for last month, up 40.8 percent year-on-year and bringing its revenue for the second quarter to NT$310.7 billion, beating the NT$308.8 billion analysts expected on average. TSMC, a barometer for the industry thanks to its heft in the global supply chain, had previously lowered its revenue outlook for this
ELECTRIC FARMLAND: TSMC’s proposal to clear 230 hectares of reforested land for what would become Taiwan’s largest photovoltaic solar farm has generated concerns New rules curbing solar farms built on agricultural land sparked fierce debate at a packed public hearing at the Legislative Yuan yesterday, with industry representatives saying that the new restrictions would endanger President Tsai Ing-wen’s (蔡英文) green energy goals, while agricultural officials emphasized the importance of protecting farmers and the environment. The Tsai administration has set a target to generate 20 percent of the nation’s power from renewable sources by 2025, by which time it also aims to install 20 gigawatts (GW) of solar power, including 6GW from rooftop solar systems and 14GW from ground-mounted solar farms. Although rooftop solar systems are